Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

Completed

Conditions studied: Open-Angle Glaucoma, Ocular Hypertension

In brief

To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers. Patients will be assessed at baseline, at each follow-up visit (follow-up visits are variable as per physician discretion) and at final follow-up visit.

Key facts

Study ID

NCT00716742

Run by

Allergan

People needed

1099

Starts

2004-09-01

Expected to finish

2009-09-01

Last updated by the study team

2012-01-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A diagnosis of Primary Open-Angle Glaucoma or Ocular Hypertension newly diagnosed OR presenting with insufficiently controlled IOP on current medication (in the opinion of the treating physician)
• Patient is having both eyes treated

You may not qualify if…

• Contraindications per product labelling will apply.
• Patients with any ophthalmic co-morbidity with an influence on visual field deterioration or optic nerve head damage.

Where it is running

• Study site — Murfreesboro, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.